QM · rank #8 · 2026-09-11
SNT
GPW · PLN · $775M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +76.34% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $775M |
| Anchor (recent) Close on 2026-08-12 | $361.60 |
| Anchor (far) Close on 2025-08-12 | $205.06 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is Poland's dominant PET/CT radiopharmaceutical producer and integrated diagnostic imaging solutions provider, operating three dedicated tracer plants and bundling isotope supply with hardware, IT, and servicing for public oncology centres.
Rationale
The 76% trailing momentum is directly underpinned by verified fundamental acceleration — 52% revenue growth, 89% Q3 year-on-year revenue surge, 27%+ EBITDA margins, and 55% ROE — making this a rare case where price momentum and quality signals are mutually reinforcing rather than divergent.
Material risks
- 1CEO Cezary Kozanecki sold 615,000 shares at 350 PLN in a June 2026 accelerated bookbuilding, and management has explicitly guided to near-term result flattening post-Syn2bio spin-off, which could stall momentum if Q4 FY2025/26 disappoints consensus.
- 2Revenue is heavily concentrated in Polish public hospital tenders and EU KPO/e-Zdrowie program disbursements, meaning any healthcare budget freeze or KPO disbursement delay directly impairs the order pipeline with limited private-sector offset.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.